SABCS: A novel, semi-automated Pipeline for HER2 Quantification on CTCs in breast cancer patients. Is cytopathology of peripheral blood a new diagnostic option?

DDR Conference – Detection of DNA Damage Response Biomarkers in Circulating Tumour Cells using ANGLE’s Parsortix® instrument and downstream immunofluorescence assays

Low‑pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple‑negative breast cancer

Identification of circulating tumor cells captured by the FDA-cleared Parsortix® PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations

DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients

Analytical performance of the FDA-cleared Parsortix®PC1 system

Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast Cancer

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients

A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix®PC1 System

Request a meeting with